Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Monthly Archives: March 2014

2012 – “Statins and Risk of New-Onset Diabetes Mellitus”

Posted in Lipitor

A 2012 article by Dr. Ravi V. Shah and Dr. Allison B. Goldfine titled “Statins and Risk of New-Onset Diabetes Mellitus” published in Circulation, a journal of the American Heart Association, provides important insight into the connection between statin use and new onset diabetes. The team writes “For any prescription drug, the potential benefits to… Continue Reading

2013 – Large study shows Lipitor raises risk for diabetes at least 14%

Posted in Lipitor

Published in the May 2013 edition of Diabetes Care, an article by G Danaei et al. titled “Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival.” aimed to determine if there was a bias in studies linking diabetes and statin drug use.  Statins are drugs… Continue Reading

2013 – Lipitor raises risk for diabetes 15%

Posted in Lipitor

A 2013 article titled “Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.” published in The American Journal of Cardiology aimed to clarify the relationship between statin drug use and new onset diabetes by analyzing a number of previously conducted studies.  Statin drugs are cholesterol-lowering medications including Lipitor, Crestor, Zocor,… Continue Reading

2014 – Scientists: “Literature suggests an increased risk of new-onset diabetes” with statin drugs

Posted in Lipitor

An article published in the March 2014 edition of Current Radiology Reports by CN Bang et al. titled “Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.” cites research linking statin use and new onset diabetes.  Statins are commonly-used cholesterol-lowering drugs including Lipitor, Zocor, Crestor, and many others. Bang et al. (2014) state… Continue Reading

2012 – FDA Updates Safety Information for Lipitor, Citing Diabetes and Other Risks

Posted in Lipitor

On  February 28th, 2012 the FDA issued a safety announcement alerting the public that Lipitor and other cholesterol-lowering statin drugs are associated with an increased risk for diabetes. Click Here for an Infographic on How Statins Work At that time, the FDA required safety label updates for statin drugs including warnings against “cognitive side effects… Continue Reading

2013 – Risk for diabetes elevated by 23% with Lipitor use

Posted in Lipitor

In 2013, an article titled “Statins and risk of treated incident diabetes in a primary care population.” appearing in British Journal of Clinical Pharmacology aimed to determine whether or not statin use raises the risk for new onset diabetes.  Statin drugs include Lipitor, Crestor, and others and are prescribed to lower low-density cholesterol.  Researchers also… Continue Reading

2012 – Diabetes risk “significantly higher in statin users”

Posted in Lipitor

In 2012, a report published by KL Wang et al. in Journal of the American College of Cardiology titled “Statins, risk of diabetes, and implications on outcomes in the general population.” aimed to further clarify the relationship between statin drugs and new onset diabetes.  Statins are a class of cholesterol-lowering drugs including Lipitor, Crestor, and… Continue Reading

FDA cites diabetes, cognitive impairment, muscle damage, liver injury associated with Lipitor

Posted in Lipitor

Recently, I found a great page at the the FDA website outlining a variety of risks associated with Lipitor and other cholesterol-lowering statin drugs. Here, the FDA cites diabetes, cognitive impairment, muscle damage, and liver injury associated with Lipitor and other similar drugs. Unfortunately, the manufacturers of these drugs have failed time and again to… Continue Reading

2012 – Lipitor helpful but dangerous

Posted in Lipitor

A 2012 paper by PM Ridker et. al published in The Lancet titled “Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.” lives up to its title and outlines the cardiovascular benefits of using statin drugs (including Lipitor, Zocor, Crestor, and others) along with the risk for… Continue Reading

2012 – Lipitor, other statins raise risk for diabetes

Posted in Lipitor

A study published in the February, 2012 edition of QJM (the monthly journal of the Association of Physicians) by M. Alberton et al. titled “Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.” set out to “identify differing risk effects across statins.”  Statins are cholesterol-lowering drugs including Lipitor (atorvastatin), Zocor,… Continue Reading

2013 – Elevated risk for heart attack, stroke in testosterone therapy

Posted in Androgel

In 2013, a team of medical researchers led by R. Vigen from The University of Texas at Southwestern Medical Center in Dallas published a report titled “Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.” in JAMA that aimed to evaluate the connection between testosterone therapy and increased… Continue Reading

2014 – Risk for heart attack 36% higher among testosterone therapy patients

Posted in Androgel

In 2014, a paper was published in the medical journal PLoS One by WD Finkle et al. titled “Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.” studied the risk for heart attack suffered by users of testosterone therapy. The authors state “An association between testosterone therapy (TT) and cardiovascular disease has… Continue Reading

2011 – Doctor to advocate for Actos paid by manufacturer

Posted in Actos & Bladder Cancer

In 2011, Robert Elford Ryder published a report in the medical journal The Lancet titled “Pioglitazone and bladder cancer” which discusses the link between diabetes drug Actos (Tadeka Pharmaceuticals, Inc.) and bladder cancer. At the outset of his piece, Ryder states “In June, 2011, the French and German regulatory bodies suspended pioglitazone over the risk… Continue Reading

2013 – Large study shows Actos raises risk for bladder cancer 30%

Posted in Actos & Bladder Cancer

In 2013, a team of researchers led by MT Bazelier published a paper titled “Use of thiazolidinediones and risk of bladder cancer: disease or drugs?”, where it is stated “Pioglitazone, a drug for the treatment of type 2 diabetes mellitus has been associated with bladder cancer in observational studies” but that “Diabetes mellitus itself has… Continue Reading

2012 – Actos shown to increase risk for bladder cancer

Posted in Actos & Bladder Cancer

In 2012, a study was published titled “Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.” that aimed to evaluate the connection between the thiazolidinedione class of diabetes drugs (e.g. Actos) and bladder cancer.  The study appeared in Journal of the National Cancer Institute and was prepared by R. Mamtani… Continue Reading

2011 – FDA: Actos raises risk for bladder cancer by 430%

Posted in Actos & Bladder Cancer

A 2011 article published in Diabetes Care by C. Piccinni et al. titled “Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.” set out to “analyze the association between pioglitazone [(Actos)] use and bladder cancer through a spontaneous adverse event reporting system for medications.” To obtain data for this study,… Continue Reading

2014 – 35% of patients suffer complications with robotic-assisted surgery

Posted in Surgical Robots

In January 2014, the results of a study by D. Ramzy et al. titled “Three hundred robotic-assisted mitral valve repairs: the Cedars-Sinai experience.” in Journal of thoracic and cardiovascular surgery that evaluated the relative safety and efficacy of robotic-assisted surgery for the repair of the heart’s mitral valve. The surgeries evaluated in this study were… Continue Reading

2014 – More complications, longer operating times with robotic-assisted surgery

Posted in Surgical Robots

In 2014, a study was published in Annals of Surgical Oncology by BH Lang et al. titled “A Systematic Review and Meta-analysis Comparing Surgically-Related Complications between Robotic-Assisted Thyroidectomy and Conventional Open Thyroidectomy.” that aimed to determine the relative safety of robotic-assisted by conventional thyroidectomy. For this study, researchers reviewed 11 previously-conducted studies and used statistics… Continue Reading